The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millennium
Open accessAbstract
Androgen therapy, using injectable, oral and more recently, transdermal preparations, has been available to physicians for many years to treat a variety of male disorders; to a lesser degree, their use has been extended to some female indications. Unlike female sex hormone therapies, which have found extensive use and applications in the fields of hormone replacement, reproductive disorders, gynecological cancers, and contraception, androgen therapy has not been widespread. A more widely accepted use of androgen therapy has been hampered by the lack of orally active preparations with good efficacy and, particularly, a safe profile. Progress has been limited over the last three decades in developing synthetic molecules that could separate androgenic activities considered desirable (i.e., anabolic) from others that were undesirable or had dose-limiting side effects (1). The abuse of synthetic anabolic steroids by athletes and body builders has contributed to the general perception of certain negative side effects (i.e., aggressive behavior), effects that we do not expect to see with replacement regimens of testosterone or other androgen receptor agonists that target judicious restoration of physiological functions normally regulated by endogenous androgens. Recent advances clearly indicate that androgen therapy is about to experience a fundamental change, both in the extent of use and in the range of applications that may benefit from these upcoming advances. Several factors have and will continue to contribute to this change. First, the significant advances of hormone replacement therapy (HRT) in postmenopausal females and the expansion and application of HRT to treat and prevent major disorders such as osteoporosis, cardiovascular disease, breast cancer, mood and cognition, among others, have clearly established the value of novel HRT therapies for improving women’s health (2–4), and by extrapolation, they clearly point out the potential for similar approaches to address men’s health disorders. Second, the development and marketing of novel selective estrogen receptor modulators (SERMs) has provided both preclinical and clinical proof-of-concept that we can develop molecules with a great degree of tissue selectivity targeting the estrogen receptor to eliminate undesired side effects and to maintain (and in the future to enhance) the positive, protective effects of selective transcriptional receptor activation (3–7). Third, significant advances in our understanding of nuclear receptor activation and function have provided the molecular underpinnings for new drug development efforts to design and bring forward a new generation of tissue-selective molecules targeting steroid and other nuclear receptors. Proof-of-concept for tissue selectivity has now been extended to many compounds interacting with different nuclear receptors, such as the estrogen (ER), progesterone (PR), androgen (AR), retinoid (RAR/RXR), and peroxisome proliferation activated receptors (PPARs), among others (6–11). With the information described above, we have been able to chart a development path and create a profile of desired activity and selective indications for a new class of molecules targeting the androgen receptor. We have chosen the term selective androgen receptor modulators (SARMs) after the terminology currently used for similar molecules targeting the estrogen receptor. Below we briefly describe the molecular mechanisms underlying the potential for selective modulation of AR by different ligands and the opportunities that novel SARMs bring to therapies for broad, as well as selective, uses of androgen therapy, in men as well as in women. The AR is a transcription factor and a member of the extended family of nuclear receptors. As such, it shares significant homology in terms of structure with the other members of the family, including specific protein subdomains that either activate or repress gene activity. Current evidence indicates that these activation domains represent surfaces in the receptor that are induced or exposed upon hormone or ligand-binding in such a manner that they facilitate the interaction of the specific domain or surface with selected proteins named coactivators or corepressors (5, 12). These proteins are part of an expanding family of molecules, and several have been found to bind directly to AR, namely CBP/p300 (13), GRIP1 (14), ARA 54,55 and 70 (15, 16), and Tip60 (17). Each selective ligand, upon binding to the receptor, may drive it into a distinct conformation that exposes activation or interaction surfaces resulting in recruitment of specific cofactors as revealed by structural studies (12). In addition, tissue expression or relative concentration of different cofactors may vary. Recently, a testis-specific cofactor, ARIP-3, has been described (18) that modulates AR-dependent transcriptional activity. Motif-driven interactions have been described that can modify the affinity of a given cofactor for
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
Khosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Structure and specificity of nuclear receptor–coactivator interactions
Darimont, B. D., Wagner, R. L., Apriletti, J. W., Stallcup, M. R., Kushner, P. J., Baxter, J. D., Fletterick, R. J., & Yamamoto, K. R. (1998) · Genes & Development · doi:10.1101/gad.12.21.3343 · Cited by 924
Katzenellenbogen, J. A. (1996) · Molecular Endocrinology · doi:10.1210/me.10.2.119 · Cited by 535
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
McDonnell, D. P. (1995) · Molecular Endocrinology · doi:10.1210/me.9.6.659 · Cited by 526
Androgens in Men — Uses and Abuses
Bagatell, C. J., & Bremner, W. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341107 · Cited by 464
Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1966 · Cited by 460
Ding, X. F., Anderson, C. M., Ma, H., Hong, H., Uht, R. M., Kushner, P. J., & Stallcup, M. R. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.2.0065 · Cited by 434
Mukherjee, R., Jow, L., Croston, G. E., & Paterniti, J. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.8071 · Cited by 420
Cloning and Characterization of Androgen Receptor Coactivator, ARA55, in Human Prostate
Fujimoto, N., Yeh, S., Kang, H.-Y., Inui, S., Chang, H.-C., Mizokami, A., & Chang, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8316 · Cited by 294
Cited by
Principles for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
Advances in Male Contraception
Page, S. T., Amory, J. K., & Bremner, W. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0041 · Cited by 1,134
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Khosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Metadata
- Authors
- Negro-Vilar, A.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-10-01
- Volume
- 84
- Issue
- 10
- Pages
- 3459-3462
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2015518137
- Cited by
- 282
- References
- 27
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millennium. https://app.cochat.ai/papers/10.1210/jc.84.10.3459
- The paper
- Negro-Vilar, A. (1999). Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millennium. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.84.10.3459
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.